[Utility of NSE, ProGRP and LDH in Diagnosis and Treatment in Patients with Small Cell Lung Cancer].
BACKGROUND
Small cell lung cancer (SCLC) is a rapidly growing tumor with characteristic of neuroendocrine cellular function. Neuron specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP) and lactic dehydrogenase (LDH) are valuable in diagnosis and treatment of SCLC. By analyzing the variation of NSE, ProGRP and LDH before and after treatment, the aim of this study is to investigate the efficacy of tumor markers in diagnostic staging, therapeutic evaluation and prediction of disease relapsing.


METHODS
Patients with SCLC who receiving the first line chemotherapy in Cancer Hospital, Chinese Academy of Medical Sciences were enrolled and retrospectively analyzed. Clinical characteristic (includes NSE, ProGRP and LDH level before and after 2 cycles chemotherapy), efficacy evaluation, progression-free survival (PFS) were analyzed.


RESULTS
Before treatment, Serum NSE, ProGRP and LDH in patients with extensive disease (ED) were significantly higher than those with limited disease (LD)(all P<0.005); NSE level increased obviously accompanied by increase of lymph nodes stage in LD group (P=0.010); Patients with weight reduction when diagnosis had higher NSE and LDH than those without loss of weight (P=0.032, P=0.014). After 2 cycles chemotherapy, decrease of NSE and ProGRP in effective group was higher than which in stable and ineffective groups (P=0.015, P=0.002). The relapse risk was lower in patients who accepted >4 cycles chemotherapy and with obvious decrease of ProGRP than those who accepted ≤4 cycles chemotherapy and with less obvious decrease of ProGRP in LD group; ED patients with no more than 2 distant metastasis, normal LDH level before treatment and obvious decrease of ProGRP after chemotherapy had lower short term relapse risk. In addition, the types of relapse (sensitive relapse, drug resistance relapse and refractory relapse) were negatively correlated with decrease of ProGRP (P=0.044). By multivariate analysis, numbers of chemotherapy cycle was independent prognostic factor for PFS in LD SCLC; numbers of distant metastasis and decrease of ProGRP were independent prognostic factors for PFS in ED SCLC.


CONCLUSIONS
Increase level of serum tumor markers is related to tumor burden. Decrease level of ProGRP after treatment may prognose efficacy and relapse risk.
Department of Medical Oncology, Beijing Chaoyang Sanhuan Cancer Hospital, Beijing 100021, China.
Yan
Y
Peng
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Yan
Y
Wang
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Junling
J
Li
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Xuezhi
X
Hao
Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, China.
Xingsheng
X
Hu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000097:blood; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood*; D010751:Phosphopyruvate Hydratase / Q000097:blood*; D011994:Recombinant Proteins / Q000097:blood; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D010446:Peptide Fragments; D011994:Recombinant Proteins; C087079:pro-gastrin-releasing peptide (31-98); D007770:L-Lactate Dehydrogenase; D010751:Phosphopyruvate Hydratase
Eur J Cancer. 2009 Jan;45(2):228-47
19097774
Clin Cancer Res. 2000 Feb;6(2):597-601
10690544
Biochim Biophys Acta. 2013 Dec;1836(2):255-72
23796706
J Clin Oncol. 2007 Sep 10;25(26):4137-45
17827464
Clin Lab. 2003;49(1-2):35-42
12593474
Oncol Lett. 2011 Sep 1;2(5):855-860
22866140
Lung Cancer. 2003 Mar;39(3):303-13
12609569
Med Oncol. 2014 Feb;31(2):823
24375395
Cancer Res. 1994 Apr 15;54(8):2136-40
8174119